Page 232 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

Chapter 8
Supplemental Table 5. Number of PET positive patients for DS4-5, DS5 and ∆SUVmax PET response criteria related to the total number of events for PFS, TTP and OS outcome parameters.
Response criteria
DS1-3 vs 4-5 DS1-4 vs 5 ∆SUVmax
Timing PFS
No true positives
I-PET1 13 I-PET2 131 I-PET36 I-PET4 42 I-PET1 6 I-PET2 38 I-PET34 I-PET4 16 I-PET15 I-PET2 59 I-PET34 I-PET4 19
No events
19
237
17
100
19
237
17
100
11
240
16
75
TTP
No true positives
11
109
3
37
6
32
1
14
4
49
1
16
No events
16
197
11
87
16
197
11
87
8
198
10
65
OS
No true positives
11
89
4
35
5
32
3
16
4
47
3
16
No events
17
152
11
70
17
152
11
70
10
155
10
53
Abbreviations: DS: Deauville Score, I-PET interim PET, OS: overall survival, PFS; progression free survival, TTP: time to progression, ∆SUVmax: reduction in Standardized Uptake Value.
Progression Free Survival
Supplemental Table 6. HRs between negative I-PET timings and between positive I-PET timings compared to I-PET2 with 2-year PFS as outcome.
I-PET1 negative I-PET2 negative I-PET3 negative I-PET4 negative I-PET1 positive I-PET2 positive I-PET3 positive I-PET4 positive
DS1-3 vs 4-5 (95% CI)
1.31 (0.57-2.98) 1 (reference) 1.11 (0.59-2.07) 0.70 (0.51-0.97) 0.93 (0.52-1.64) 1 (reference) 1.90 (0.84-4.31) 1.21 (0.85-1.71)
DS1-4 vs 5 (95% CI)
1.08 (0.62-1.90) 1 (reference) 1.05 (0.60-1.84) 0.74 (0.57-0.96) 0.55 (0.23-1.29) 1 (reference) 1.00 (0.36-2.81) 0.94 (0.52-1.69)
∆SUVmax (95% CI)
1.06 (0.47-2.40) 1 (reference) 1.20 (0.67-2.15) 0.72 (0.53-0.98) 0.53 (0.21-1.32) 1 (reference) 0.92 (0.34-2.55) 1.14 (0.68-1.92)
Abbreviations are explained in Supplemental Table 5.
230